ASNC/Pfizer Young Investigator in Cardiac Amyloidosis Research Fellowship Award


The award provides $35,000 of support to eligible investigators for a mentored research project exploring the role of nuclear cardiology in the early detection of TTR cardiac amyloidosis. 

The recipient will have the distinct honor of presenting the status of their research at the 29th Annual Scientific Session and Exhibition of the American Society of Nuclear Cardiology.

Applications are closed.

Goals

  • Increase opportunities for clinical research focused on cardiac amyloidosis and to improve early diagnosis, timely referral to amyloid experts, and knowledge of emerging treatment options.
  • Improve outcomes of patients with ATTR-CM.
  • Encourage and support careers in nuclear cardiology research while growing the science of cardiac imaging and advancing the specialty.


Objectives

  • Promote research in nuclear cardiology among young investigators.
  • Create platform for research projects in the area of advancing early detection of TTR cardiac amyloidosis utilizing nuclear cardiology.
  • Provide an "initial" grant for young investigators that will serve as a stepping stone to larger awards.
  • Promote the field of nuclear cardiology by supporting new and innovative research. 


Award Amount/Project Duration

$35,000 for one year


Number of Awards

One (1)


Award Eligibility

Individuals who:
  • Hold an MD, PhD or equivalent degree
  • Are post-doctoral fellows or faculty in the first three years of appointment on the date of the application deadline
  • Intend to pursue an academic career in nuclear cardiology
  • Have an active ASNC membership
Individuals with prior independent investigator awards (e.g., NIH, R0l) will not be eligible to apply for this funding. The applicant may not have current overlapping funding from another organization to supplement their proposed work.


Judging Criteria

Applications will be reviewed against the following criteria:
  • Scientific merit (significance) with focus on the potential for the project to generate data for a successful peer-reviewed grant application
  • Approach/methods
  • Innovation and role in early detection or monitoring of TTR cardiac amyloidosis
  • Investigator qualifications with focus on the potential for the principal investigator to develop into an independent investigator
  • Quality of mentor and training environment – letter of reference from mentor
  • Research benefit for the field of nuclear cardiology
A rating scale such as the one below will be utilized by the award committee for scoring each application. A numerical scoring system from 1.0 to 5.0 -- 1.0 is highest; 2.5 is mid-range; 5.0 is lowest.


Expectations of the Awardee

  1. You will use the full $35,000 award during the one-year term of the award. All unexpended funds at the end of the term are to be returned to ASNC. Extensions or changes to the terms of the award (length of funding period and budget) will only be made in exceptional circumstances.
  2. You must submit 1) a progress and financial report on or before March 31, 2024, describing your work to date, and 2) your final research and finance reports on or before September 1, 2024.
  3. You are expected to report the results of your work with your mentor during an educational session at the 29th Annual Scientific Session and Exhibition of the American Society of Nuclear Cardiology to be held September 5-7, 2024.
  4. All publications, presentations, and products resulting from this research should acknowledge the ASNC/Pfizer Young Investigator in Cardiac Amyloidosis Research Award. 

Congratulations to Olivier F. Clerc, MD, the recipient of the 2022 ASNC/Pfizer Young Investigator in Cardiac Amyloidosis Research Award
   

 

Sponsored by: Pfizer Inc.